Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Cartalax4 residuesAEDPEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: AED, AC-4, Cytogen Cartalax
An 18 to 38 percent increase in cartilage area index in rat tissue cultures. That is the best number Cartalax has produced so far. Cartalax (Ala-Glu-Asp) is a synthetic tripeptide from Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. It targets chondrocyte gene expression, upregulating proliferation markers and suppressing apoptotic signals in preclinical models. All evidence is in vitro or animal. No human clinical trial has been conducted. The community using it is small, mostly centered on LongeCity and Russian bioregulator forums, and typically stacks it with Epithalon for longevity protocols.
Three amino acids. Alanine, glutamic acid, aspartic acid. That is the entire structure of Cartalax (AED), a synthetic tripeptide derived from sequences in the alpha-1 chain of type XI collagen. Khavinson's group at the St. Petersburg Institute developed Cartalax as part of a broader bioregulator program. The theory: short peptides penetrate cell nuclei and bind promoter regions of tissue-specific genes. For Cartalax, the targets are chondrocyte genes controlling proliferation, apoptosis, and extracellular matrix turnover. Myakisheva and colleagues [1] confirmed that AED activated chondrogenic differentiation genes in aging human mesenchymal stem cells at 200 ng/mL concentrations in vitro. In rat cartilage tissue cultures, the results are consistent. PCNA and Ki-67 go up (proliferation). p53 and caspase-3 go down (apoptosis). MMP-9 synthesis drops, potentially slowing cartilage matrix breakdown. The net effect in those cultures: an 18 to 38 percent increase in cartilage area index. Encouraging numbers from a dish; unconfirmed in any living human. Community experience is thin. Fewer than 50 identifiable English-language anecdotal reports exist across LongeCity and r/Peptides. Those who use it follow the standard Khavinson protocol: 10 to 20 mg oral daily for 30 days, then 3 to 6 months off. Some report reduced joint stiffness around weeks 2 to 4. Placebo cannot be ruled out. Khavinson died in January 2024, and research output from his group has slowed since.
Cartalax operates through Khavinson's peptide bioregulation model. The AED tripeptide is small enough to cross cell and nuclear membranes. Once inside the nucleus, it is proposed to bind specific DNA sequences in promoter regions of cartilage-related genes. The downstream effects in cell culture are measurable. PCNA and Ki-67 expression increases, driving chondrocyte division. p53 and caspase-3 decrease simultaneously, reducing programmed cell death. That combination creates a pro-survival, pro-proliferative state in cartilage tissue. Sirtuin activity also responds to Cartalax. SIRT-1 and SIRT-6 expression rises in fibroblast and chondrocyte cultures. Both sirtuins are linked to DNA repair and cellular stress resistance, relevant pathways in aging cartilage. On the matrix side, Cartalax inhibits MMP-9 synthesis. MMP-9 is a matrix metalloproteinase that degrades collagen and proteoglycans; slowing its activity could help preserve the structural framework of cartilage. Whether any of these in vitro effects translate to cartilage preservation in a living joint remains unknown.
Preclinical evidence (in vitro + rat) supports chondrocyte proliferation, MMP-9 inhibition, and anti-apoptotic effects. No human clinical trials. Research stalled after Khavinson's death in January 2024.
Myakisheva et al. 2023 (PMID 37782646): AED activates chondrogenic differentiation genes in aging human MSCs at 200 ng/mL in vitro; 18–38% cartilage area index increase in rat models
All evidence is in vitro or animal. No RCTs, no PK studies in humans, no dose-response data in humans. Research group output paused post-Khavinson (Jan 2024). Western replication absent.
Very limited English-language community data. Oral Cytogen capsule protocol (10–20 mg/day × 30 days) is the de facto standard. Anecdotal reports focus on reduced joint stiffness onset weeks 2–4.
The small community that uses Cartalax targets cartilage/joint support, consistent with the preclinical mechanism. However, community data is too thin to validate dosing or efficacy. Neither side has human clinical trial evidence.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Cartalax is an oral capsule. No reconstitution, no syringes, no bacteriostatic water for the standard protocol. You take 1 to 2 Cytogen capsules (10 to 20 mg) daily for 30 days, then stop for 3 to 6 months. That long off-period is built into the Khavinson model; the theory holds that epigenetic changes persist well beyond the dosing window. Watch the labeling. Some vendors list "0.1 mg" per capsule (pure AED peptide weight) while others list "10 mg" (total peptide complex weight). That is a 100x difference in apparent dose. Confirm which measurement your vendor uses before adjusting anything. If you go the injectable route (research use only, no clinical validation), reconstitute a 20 mg vial with 2 mL bacteriostatic water for 10 mg/mL concentration. On a U-100 insulin syringe, 100 units equals the full 10 mg dose. Each vial covers two injections at 10 mg per day, or one injection per day for 14 days if you split into two vials. Injectable courses run 10 to 14 days, shorter than oral. Source oral capsules from established Russian vendors (Cytogen/GARMONIA via CosmicNootropic or ipept.com). For injectable vials, request a COA with HPLC purity at or above 98 percent and mass spec confirmation of the AED sequence.
Standard Russian bioregulator cycling protocol: 30 days on, 2-3 months off. Some protocols recommend repeating 2-3 cycles per year.
Khavinson's bioregulation theory proposes that a 30-day course triggers epigenetic gene expression changes (via peptide-DNA promoter binding in chondrocyte nuclei) that persist for months post-cycle. Extended off-periods (3–6 months) allow these epigenetic changes to stabilize. Re-dosing before stabilization is considered unnecessary and potentially disruptive per this model. The long rest also serves as a precautionary safety measure given the complete absence of long-term human data.
Or use the universal Peptide Calculator for any peptide.
Expected: No measurable human outcome data. Preclinical theory: gene expression changes in chondrocytes established by end of course; epigenetic effects proposed to persist through off-period.
Monitor: Subjective joint stiffness or pain (VAS scale). No blood tests required.
Oral protocol (standard): Take 1 capsule (10 mg) with water, 30 minutes before breakfast on an empty stomach. For the moderate dose, take 2 capsules (20 mg) at the same time. Continue daily for 30 days. No food for 30 minutes after dosing.
Injectable protocol (research use only): Reconstitute a 20 mg lyophilized vial with 2 mL bacteriostatic water. Swirl gently; do not shake. This yields 10 mg/mL. On a U-100 insulin syringe, draw 100 units for a 10 mg dose. Inject subcutaneously in the abdomen or thigh using a 29 to 31 gauge needle, half-inch length. Rotate injection sites daily. Store reconstituted vial in the refrigerator.
Cycling: Complete the full 30-day oral course (or 10 to 14 day injectable course). Rest for a minimum of 3 months before repeating. Most protocols recommend 2 to 3 courses per year.
10–20 mg/day; 30-day courses; 3–6-month rest
Oral bioavailability not formally measured for AED tripeptide. PepT1 transporter analysis estimates ~30–50% intact tripeptide absorption: extrapolated, not measured. Standard and recommended route.
10 mg/day SC; 10–14-day courses (shorter than oral: higher assumed bioavailability)
No pharmacokinetic comparison vs oral has been conducted. Injectable bypasses GI degradation, theoretically more reliable peptide delivery. Dose entirely community-empirical. Not commercially developed or label-supported.
Khavinson anti-aging longevity stack. Epithalon targets pineal/telomere biology; Cartalax targets cartilage tissue. Commonly cycled together in Russian bioregulator protocols.
BPC-157 (angiogenesis, acute repair) + Cartalax (chondrocyte gene regulation, maintenance). LongeCity users report complementary benefit for knee cartilage: anecdotal only.
BPC-157 250–500 mcg/day SC for acute phase; Cartalax oral 10–20 mg/day for maintenance. Not necessarily concurrent.
TB-500 systemic tissue repair + Cartalax chondrocyte targeting. Community-reported as a repair + maintenance stack for joint injury recovery.
GHK-Cu supports collagen synthesis and ECM remodeling (TGF-β pathway); Cartalax inhibits MMP-9 (matrix degradation). Mechanistically complementary for cartilage ECM preservation.
Theoretical shared anti-inflammatory/matrix pathway overlap. No formal interaction data. Chronic NSAID use impairs cartilage matrix synthesis independently, potentially opposing Cartalax's proposed mechanism.
Pricing updated 2026-04-09
The honest answer: almost nothing is known about Cartalax side effects in humans. No controlled safety trial has been conducted. No adverse event monitoring system has tracked its use. The total formal human safety data is zero participants. Preclinical studies report no adverse effects in cell cultures or animal models. That provides limited reassurance. In vitro toxicity screening catches severe cytotoxicity; it does not predict allergic reactions, organ effects, or drug interactions in living people. Community reports are equally sparse. Fewer than 50 identifiable English-language anecdotal reports exist, and none describe serious adverse effects. That absence of reports reflects the tiny user base more than confirmed safety. When only a handful of people try something and do not post online, you cannot conclude it is safe. Oral bioavailability for the AED tripeptide has not been formally measured. PepT1 transporter analysis estimates 30 to 50 percent intact absorption, but that figure is extrapolated, not directly measured. Gastrointestinal discomfort is a theoretical concern with any oral peptide, though no users have reported it specifically with Cartalax. For the injectable route (used by a small subset of Western researchers), standard injection site risks apply: local erythema, induration, or nodule formation. Rotate injection sites. No systemic reactions have been documented, but the sample size is negligible. Theoretical concerns exist around the proliferative mechanism. Cartalax promotes chondrocyte division and suppresses apoptosis. Anyone with active malignancy involving cartilage or bone should avoid it as a precaution. Pregnancy and breastfeeding are contraindicated due to complete absence of reproductive safety data. Known hypersensitivity to alanine, glutamic acid, or aspartic acid is a contraindication, though this is rare. Children and adolescents have not been studied. The peptide has no formal drug interaction data. NSAID co-administration is a theoretical concern because both act on inflammatory and matrix pathways in joints. Chronic NSAID use impairs cartilage matrix synthesis independently, potentially working against the proposed Cartalax mechanism.
Verify Cartalax dosing and safety with a second opinion
Two distinct product types (Russian oral capsules vs Western injectable research vials) with inconsistent labeling, no independent US-based third-party testing standards, and supply chain uncertainty following Khavinson's death (January 2024). Capsule strength labeling varies 100x across vendors (0.1 mg vs 10 mg per cap) reflecting active AED vs peptide complex weight.
| Test | When | Target |
|---|---|---|
| Subjective joint pain/stiffness score (VAS or WOMAC) | Baseline (Day 0), mid-course (Day 14), end of course (Day 30), 3 months post-course | — |
| Injection site assessment | Each injection session (injectable protocol only) | — |
No blood-based biomarker exists for Cartalax efficacy. Self-reported scoring is the only practical tracking tool.
Monitor for local erythema, induration, or nodule formation. Rotate injection sites to prevent tissue accumulation.
No noticeable effects expected. Bioregulator peptides are theorized to work at the gene expression level, which takes time to produce measurable changes.
Some anecdotal reports mention reduced joint stiffness. These early reports are not backed by clinical data and may reflect placebo response.
If the bioregulator theory holds, gene expression changes related to cartilage maintenance should be established. No objective human outcome data exists.
Khavinson theory proposes that effects persist after stopping, as epigenetic changes stabilize. This claim is based on animal and cell culture data.
Week 1: Nothing to feel yet. Gene expression changes may begin at the cellular level within days (based on in vitro data), but tissue-level effects take longer to develop. No pharmacokinetic data exists in humans. Users experienced with bioregulators expect slow onset and set expectations ahead of time. Weeks 2 to 4: Some LongeCity users mention reduced joint stiffness emerging around this window. Preclinical models show PCNA and Ki-67 upregulation established by roughly day 14, with MMP-9 inhibition ongoing through the course. Whether stiffness changes reflect the peptide or placebo is unknown without controlled data. Day 30 (end of course): The full 30-day course is complete. Per Khavinson's model, epigenetic gene expression changes in chondrocytes should be stabilized. No human biomarker exists to confirm this. Community reports are split; some perceive sustained joint comfort, others notice nothing meaningful. Months 1 to 6 (off-period): The long rest is the point, not an afterthought. Khavinson's theory holds that epigenetic modifications persist for months after stopping, making the off-period biologically productive rather than idle. Animal data supports persistence of gene expression changes. Some users report sustained joint comfort through the off-period. The minimum rest before repeating is 3 months per the official Russian protocol label.
Gene expression changes begin in vitro within days, but tissue-level effects take longer. No pharmacokinetic data in humans.
No notable reports of week-1 effects. Users familiar with bioregulators expect slow onset.
Preclinical: PCNA/Ki-67 upregulation and p53/caspase-3 downregulation established in culture models by ~day 14. MMP-9 inhibition ongoing through course.
Some LongeCity anecdotes mention reduced joint stiffness onset weeks 2–4. Placebo cannot be excluded given absence of controls.
Epigenetic gene expression changes theoretically stabilized per Khavinson model. No human biomarker data to confirm.
Community reports are mixed; some perceive sustained joint comfort, others notice nothing. No systematic outcome data.
Khavinson theory: epigenetic changes persist for months post-course, making extended rest biologically rational. Animal data only: not confirmed in humans.
Anecdotal reports suggest sustained joint comfort through the off-period in some users. No controls; unverifiable.
Source: Estimated from tripeptide class pharmacokinetics. No direct PK study exists for Cartalax (AED).
Loading the interactive decay curve.
Cartalax is classified as a research peptide in the United States and most Western countries. It has no FDA approval, no IND application on file, and no pending clinical trials registered on ClinicalTrials.gov. In Russia, it is commercially available as an oral supplement (Cytogen brand, manufactured by GARMONIA Ltd) without prescription. Russian regulatory classification differs from Western pharmaceutical frameworks. The peptide is not currently listed on the WADA prohibited substances list. Athletes in tested competition should verify their sport's specific anti-doping rules before use. For research purchase in the US, injectable lyophilized vials are available from research chemical vendors. These are sold labeled "for research purposes only, not for human consumption." This content is for informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide product.
Peptide Schedule Research TeamReviewed Apr 20265 Citations
